ClinicalTrials.gg
CompletedNCT00552617Updated Nov 25, 2019Results posted

A Bridging Trial Comparing Sugammadex (Org 25969) at Reappearance of T2 in Japanese and Caucasian Participants. Part B: Caucasian Participants (P05971)

A Phase 2 interventional study of Sugammadex and Placebo in Anesthesia, General, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-11-25.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 1 month after the study started (first participant enrolled Sep 2005, registered Oct 2007).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
20 Years to 65 Years
Sex
All
01

Study summary

The objective of the trial was to establish the dose-response relation of sugammadex (Org 25969) given as a reversal agent of rocuronium or vecuronium at reappearance of T2 (the amplitude of the first response of second twitch to train of four (TOF) stimulation, expressed as percentage of control first twitch, T1) during sevoflurane anesthesia for Caucasian participants.

Read the detailed description

For most surgical procedures a depth of neuromuscular block of 1-2 twitches after TOF-stimulation is sufficient to avoid unwanted muscular activity. At reappearance of T2, the anesthesiologist might decide to either give (another) maintenance dose of rocuronium or vecuronium when surgery continues, to await spontaneous recovery of neuromuscular block or to reverse the neuromuscular block. Sugammadex has been shown in previous trials to greatly reduce the time to full recovery when administered at reappearance of T2, both after rocuronium- and vecuronium induced neuromuscular blockade. The current trial P05971 was conducted in Europe and set up to establish the dose response relationship of sugammadex given during sevoflurane anesthesia at reappearance of T2 after rocuronium or vecuronium in Caucasian participants. In addition to recovery time, also pharmacokinetics and safety of sugammadex were to be evaluated.

02

Conditions studied

  • Anesthesia, General
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
20 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is of (ASA) class 1 - 3;
  • Is at least 20 years but under 65 years of age;
  • Caucasian participants;
  • Is scheduled for elective surgery requiring muscle relaxation in supine position and under sevoflurane anesthesia with an anticipated duration of about 1.5-3 hours;
  • Has given written .

Exclusion criteria

Exclusion criteria:

  • Participants in whom a difficult intubation because of anatomical malformations was expected;
  • Is known or suspected to have neuromuscular disorders impairing neuromuscular blocking (NMB) and/or significant renal dysfunction (for example a creatinine level > 1.6 mg/dl) and/or severe hepatic dysfunction.
  • Is known or suspected to have a (family) history of malignant hyperthermia;
  • Is known or suspected to have an allergy to narcotics, muscle relaxants or other medication used during general anesthesia;
  • Is receiving medication expected to interfere with the rocuronium or vecuronium given in this trial, based on the dose and time of administration;
  • Females who were pregnant;
  • Females of not using or using only oral contraception as birth control;
  • Was breast-feeding;
  • Has already participated in P05971, or in another trial with sugammadex;
  • Has participated in another clinical trial, not preapproved by the Sponsor, within 6 months of entering into P05971.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (actual)

Study arms

  • Placebo comparator
    Rocuronium + Placebo

    After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered intravenously (IV), followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.

    Drug: Placebo · Drug: Rocuronium

  • Experimental
    Rocuronium + 0.5 mg/kg Sugammadex

    After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.

    Drug: Sugammadex · Drug: Rocuronium

  • Experimental
    Rocuronium + 1.0 mg/kg Sugammadex

    After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.

    Drug: Sugammadex · Drug: Rocuronium

  • Experimental
    Rocuronium + 2.0 mg/kg Sugammadex

    After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.

    Drug: Sugammadex · Drug: Rocuronium

  • Experimental
    Rocuronium + 4.0 mg/kg Sugammadex

    After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV, followed by maintenance doses of 0.1-0.2 mg/kg rocuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.

    Drug: Sugammadex · Drug: Rocuronium

  • Placebo comparator
    Vecuronium + Placebo

    After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of placebo was administered IV.

    Drug: Placebo · Drug: Vecuronium

  • Experimental
    Vecuronium + 0.5 mg/kg Sugammadex

    After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 0.5 mg/kg sugammadex was administered IV.

    Drug: Sugammadex · Drug: Vecuronium

  • Experimental
    Vecuronium + 1.0 mg/kg Sugammadex

    After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 1.0 mg/kg sugammadex was administered IV.

    Drug: Sugammadex · Drug: Vecuronium

  • Experimental
    Vecuronium + 2.0 mg/kg Sugammadex

    After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 2.0 mg/kg sugammadex was administered IV.

    Drug: Sugammadex · Drug: Vecuronium

  • Experimental
    Vecuronium + 4.0 mg/kg Sugammadex

    After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV, followed by maintenance doses of 0.02-0.03 mg/kg vecuronium IV if necessary. At reappearance of T2 a single dose of 4.0 mg/kg sugammadex was administered IV.

    Drug: Sugammadex · Drug: Vecuronium

Interventions

  • After induction of anesthesia an intubation dose of (Neuromuscular blocking agent) NMBA was administered IV: either 0.9 mg/kg rocuronium or 0.1 mg/kg vecuronium. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of sugammadex 0.5 to 4 mg/kg IV was administered

    Also known as: Org 25969

  • DrugPlacebo

    After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arm 1) or 0.1 mg/kg vecuronium (arm 6). Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary. At reappearance of T2 the randomized single dose of Placebo IV was administered

  • After induction of anesthesia an intubation dose of 0.9 mg/kg rocuronium was administered IV. Maintenance doses of 0.1-0.2 mg/kg rocuronium IV could be administered if necessary.

  • After induction of anesthesia an intubation dose of 0.1 mg/kg vecuronium was administered IV. Maintenance doses of 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.

06

What researchers measure

Primary outcomes

  1. Time From Start of Administration of Sugammadex or Placebo to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9

    Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from neuromuscular blockade (NMB). In this study, twitch responses were recorded until the T4/T1 Ratio reached \>= 0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.9 indicates a faster recovery from NMB.

    Time frame: Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.9 (up to 24 hours)

Secondary outcomes

  1. Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.7

    Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.7 indicates a faster recovery from NMB.

    Time frame: Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.7 (up to 24 hours)

  2. Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.8

    Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.8 indicates a faster recovery from NMB.

    Time frame: Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.8 (up to 24 hours)

07

Results

Posted Feb 15, 2019

Participant flow

Caucasian participants who had a surgical procedure using a general anesthesia of rocuronium or vecuronium for endotracheal intubation and maintenance of neuromuscular block were enrolled in this study.

Participant flow — Overall Study
MilestoneRocuronium + PlaceboRocuronium + 0.5 mg/kg SugammadexRocuronium + 1.0 mg/kg SugammadexRocuronium + 2.0 mg/kg SugammadexRocuronium + 4.0 mg/kg SugammadexVecuronium + PlaceboVecuronium + 0.5 mg/kg SugammadexVecuronium + 1.0 mg/kg SugammadexVecuronium + 2.0 mg/kg SugammadexVecuronium + 4.0 mg/kg Sugammadex
Started10101010101010101010
Treated101091010101010109
Completed101099108101089
Not completed0011020021
Withdrew: Not treated0010000001
Withdrew: Lost to follow-up0001020020

Outcome measures

PrimaryTime From Start of Administration of Sugammadex or Placebo to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9

Neuromuscular functioning was monitored by applying repetitive Train-Of-Four (TOF) electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from neuromuscular blockade (NMB). In this study, twitch responses were recorded until the T4/T1 Ratio reached \>= 0.9, the minimum acceptable ratio that indicated recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.9 indicates a faster recovery from NMB.

Time frame:
Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.9 (up to 24 hours)
Reported as:
Mean · Minutes
Time From Start of Administration of Sugammadex or Placebo to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.9
MinutesRocuronium + PlaceboRocuronium + 0.5 mg/kg SugammadexRocuronium + 1.0 mg/kg SugammadexRocuronium + 2.0 mg/kg SugammadexRocuronium + 4.0 mg/kg SugammadexVecuronium + PlaceboVecuronium + 0.5 mg/kg SugammadexVecuronium + 1.0 mg/kg SugammadexVecuronium + 2.0 mg/kg SugammadexVecuronium + 4.0 mg/kg Sugammadex
Time From Start of Administration of Sugammadex or Placebo to Recovery of the Fourth Twitch/First Twitch (T4/T1) Ratio to 0.996.30 ± 33.1316.30 ± 20.604.62 ± 5.971.43 ± 0.501.50 ± 0.4079.02 ± 25.9735.50 ± 42.135.07 ± 2.383.42 ± 1.853.03 ± 2.18
SecondaryTime From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.7

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.7 indicates a faster recovery from NMB.

Time frame:
Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.7 (up to 24 hours)
Reported as:
Mean · Minutes
Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.7
MinutesRocuronium + PlaceboRocuronium + 0.5 mg/kg SugammadexRocuronium + 1.0 mg/kg SugammadexRocuronium + 2.0 mg/kg SugammadexRocuronium + 4.0 mg/kg SugammadexVecuronium + PlaceboVecuronium + 0.5 mg/kg SugammadexVecuronium + 1.0 mg/kg SugammadexVecuronium + 2.0 mg/kg SugammadexVecuronium + 4.0 mg/kg Sugammadex
Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.765.67 ± 35.733.08 ± 2.252.08 ± 1.121.12 ± 0.401.02 ± 0.1258.12 ± 21.9012.57 ± 24.482.35 ± 0.482.00 ± 1.251.70 ± 0.55
SecondaryTime From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.8

Neuromuscular functioning was monitored by applying repetitive TOF electrical stimulations to the ulnar nerve every 15 seconds and assessing twitch response at the adductor pollicis muscle. T1 and T4 refer to the amplitudes (heights) of the first and fourth twitches, respectively, after TOF nerve stimulation. The T4/T1 Ratio (expressed as a decimal of up to 1.0) indicates the extent of recovery from NMB. A faster time to recovery of the T4/T1 Ratio to 0.8 indicates a faster recovery from NMB.

Time frame:
Day 1: From start of sugammadex or placebo administration to recovery of T4/T1 ratio to 0.8 (up to 24 hours)
Reported as:
Mean · Minutes
Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.8
MinutesRocuronium + PlaceboRocuronium + 0.5 mg/kg SugammadexRocuronium + 1.0 mg/kg SugammadexRocuronium + 2.0 mg/kg SugammadexRocuronium + 4.0 mg/kg SugammadexVecuronium + PlaceboVecuronium + 0.5 mg/kg SugammadexVecuronium + 1.0 mg/kg SugammadexVecuronium + 2.0 mg/kg SugammadexVecuronium + 4.0 mg/kg Sugammadex
Time From Start of Administration of Sugammadex or Placebo to Recovery of the T4/T1 Ratio to 0.875.85 ± 36.656.25 ± 9.122.62 ± 1.801.28 ± 0.421.15 ± 0.2564.33 ± 21.7225.65 ± 35.403.10 ± 0.885.83 ± 11.432.12 ± 0.80

Adverse events

Collected over Up to 7 days after sugammadex or placebo treatment. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Rocuronium + Placebo0/10 (0%)0/10 (0%)9/10 (90%)
Rocuronium + 0.5 mg/kg Sugammadex0/10 (0%)0/10 (0%)10/10 (100%)
Rocuronium + 1.0 mg/kg Sugammadex0/9 (0%)0/9 (0%)6/9 (66.7%)
Rocuronium + 2.0 mg/kg Sugammadex1/10 (10%)1/10 (10%)10/10 (100%)
Rocuronium + 4.0 mg/kg Sugammadex0/10 (0%)0/10 (0%)10/10 (100%)
Vecuronium + Placebo0/10 (0%)0/10 (0%)8/10 (80%)
Vecuronium + 0.5 mg/kg Sugammadex0/10 (0%)2/10 (20%)10/10 (100%)
Vecuronium + 1.0 mg/kg Sugammadex0/10 (0%)0/10 (0%)6/10 (60%)
Vecuronium + 2.0 mg/kg Sugammadex0/10 (0%)0/10 (0%)9/10 (90%)
Vecuronium + 4.0 mg/kg Sugammadex0/9 (0%)0/9 (0%)7/9 (77.8%)
Most frequent serious events
Most frequent serious events
EventRocuronium + PlaceboRocuronium + 0.5 mg/kg SugammadexRocuronium + 1.0 mg/kg SugammadexRocuronium + 2.0 mg/kg SugammadexRocuronium + 4.0 mg/kg SugammadexVecuronium + PlaceboVecuronium + 0.5 mg/kg SugammadexVecuronium + 1.0 mg/kg SugammadexVecuronium + 2.0 mg/kg SugammadexVecuronium + 4.0 mg/kg Sugammadex
Large intestine perforationGastrointestinal disorders0/100/100/90/100/100/101/100/100/100/9
Bladder tamponadeRenal and urinary disorders0/100/100/90/100/100/101/100/100/100/9
Urinary bladder haemorrhageRenal and urinary disorders0/100/100/90/100/100/101/100/100/100/9
Pulmonary embolismRespiratory, thoracic and mediastinal disorders0/100/100/91/100/100/100/100/100/100/9
Most frequent other events
Showing 10 of 104
Most frequent other events
EventRocuronium + PlaceboRocuronium + 0.5 mg/kg SugammadexRocuronium + 1.0 mg/kg SugammadexRocuronium + 2.0 mg/kg SugammadexRocuronium + 4.0 mg/kg SugammadexVecuronium + PlaceboVecuronium + 0.5 mg/kg SugammadexVecuronium + 1.0 mg/kg SugammadexVecuronium + 2.0 mg/kg SugammadexVecuronium + 4.0 mg/kg Sugammadex
NauseaGastrointestinal disorders3/105/103/96/104/103/104/101/102/104/9
Procedural painInjury, poisoning and procedural complications4/105/103/96/106/104/102/103/104/103/9
VomitingGastrointestinal disorders2/104/101/92/101/101/103/100/100/104/9
ConstipationGastrointestinal disorders1/103/100/90/100/100/100/101/101/100/9
HeadacheNervous system disorders0/100/100/93/102/100/101/100/100/100/9
VertigoEar and labyrinth disorders1/100/102/90/100/100/102/100/100/100/9
Abdominal painGastrointestinal disorders0/101/101/92/100/100/102/100/101/100/9
Post procedural nauseaInjury, poisoning and procedural complications1/100/100/90/100/102/100/101/100/100/9
Post procedural vomitingInjury, poisoning and procedural complications0/100/100/90/100/101/100/102/100/100/9
Procedural hypotensionInjury, poisoning and procedural complications1/100/100/91/102/100/100/100/101/100/9

Baseline characteristics

All Participants As Treated

Age, Continuous
Age, Continuous(Years)Rocuronium + PlaceboRocuronium + 0.5 mg/kg SugammadexRocuronium + 1.0 mg/kg SugammadexRocuronium + 2.0 mg/kg SugammadexRocuronium + 4.0 mg/kg SugammadexVecuronium + PlaceboVecuronium + 0.5 mg/kg SugammadexVecuronium + 1.0 mg/kg SugammadexVecuronium + 2.0 mg/kg SugammadexVecuronium + 4.0 mg/kg SugammadexTotal
Mean50 ± 752 ± 750 ± 949 ± 849 ± 1348 ± 1047 ± 946 ± 945 ± 1047 ± 1048 ± 9
Sex: Female, Male
Sex: Female, Male(Participants)Rocuronium + PlaceboRocuronium + 0.5 mg/kg SugammadexRocuronium + 1.0 mg/kg SugammadexRocuronium + 2.0 mg/kg SugammadexRocuronium + 4.0 mg/kg SugammadexVecuronium + PlaceboVecuronium + 0.5 mg/kg SugammadexVecuronium + 1.0 mg/kg SugammadexVecuronium + 2.0 mg/kg SugammadexVecuronium + 4.0 mg/kg SugammadexTotal
Female887568777770
Male222542333228
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Rocuronium + PlaceboRocuronium + 0.5 mg/kg SugammadexRocuronium + 1.0 mg/kg SugammadexRocuronium + 2.0 mg/kg SugammadexRocuronium + 4.0 mg/kg SugammadexVecuronium + PlaceboVecuronium + 0.5 mg/kg SugammadexVecuronium + 1.0 mg/kg SugammadexVecuronium + 2.0 mg/kg SugammadexVecuronium + 4.0 mg/kg SugammadexTotal
Hispanic or Latino00000000000
Not Hispanic or Latino10109101010101010998
Unknown or Not Reported00000000000
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Puhringer FK, Gordon M, Demeyer I, Sparr HJ, Ingimarsson J, Klarin B, van Duijnhoven W, Heeringa M. Sugammadex rapidly reverses moderate rocuronium- or vecuronium-induced neuromuscular block during sevoflurane anaesthesia: a dose-response relationship. Br J Anaesth. 2010 Nov;105(5):610-9. doi: 10.1093/bja/aeq226. Epub 2010 Sep 28. PubMed 20876699 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2005 to primary completion in Aug 2006, 11 months.

Results were first posted in Feb 2019, 12 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 31, 2007
First posted
Nov 2, 2007
StartActual
Sep 20, 2005
Primary completionActual
Aug 31, 2006
CompletionActual
Aug 31, 2006
Results first posted
Feb 15, 2019
Last update
Nov 25, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 25, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00552617
Responsible party
Sponsor
First posted
Nov 2, 2007
Start date
Sep 20, 2005
Primary completion
Aug 31, 2006
Completion
Aug 31, 2006
Results posted
Feb 15, 2019
Last update
Nov 25, 2019

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sugammadex · Rocuronium · Vecuronium

Start the discussion